---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-002955"
form_type: "8-K"
ticker: "OTLC"
cik: "0000908259"
company_name: "Oncotelic Therapeutics, Inc."
filed_at: "2022-02-02T23:59:59+00:00"
generated_at: "2026-06-27T12:42:31.570653+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Oncotelic issues $0.5M convertible note to Golden Mountain Partners as part of $1.5M funding

## Summary
- Issued $0.5M unsecured convertible note to Golden Mountain Partners, part of up to $1.5M total in three monthly installments.
- Note carries 2% annual interest, matures one year from date, convertible into common stock at closing bid price.
- Proceeds to support payroll and clinical development of OT-101.
- Note contains standard events of default; prepayment allowed with accrued interest.
- Conversion shares unregistered, issued under Rule 506.

## SEC filing metadata
- accession: 0001493152-22-002955
- form_type: 8-K
- ticker: OTLC
- cik: 0000908259
- company_name: Oncotelic Therapeutics, Inc.
- filed_at: 2022-02-02T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/908259/000149315222002955/0001493152-22-002955-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/908259/000149315222002955/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-002955
- JSON: https://secwatch.observer/filing/0001493152-22-002955.json
- Plain text: https://secwatch.observer/filing/0001493152-22-002955.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.